top of page
Anchor 1

Scientific Advisory Board

Professor John Griffin
Chief Scientific Officer
  • Professor, Dept of Molecular Medicine, The Scripps Research Institute at La Jolla.

  • NMR studies of peptide and protein structure at the French AEC Laboratory.

  • Published over 350 papers in Activated Protein C and APC mutants.

  • Inventor of 3K3A-Activated Protein C and TR47 - the PAR1 agonist peptide.

  • Co-inventor of the G10 PAR1-PAR3 structure. 

  • Holds appointment at the Department of Medicine, UC San Diego

Professor Christopher Jackson
BAppSc, MAppSc, PhD
Program Lead - Dermatitis and Burns
  • Professor, Regenerative Science and Medicine, Kolling Institute, University of Sydney.

  • Director, Sutton Laboratories, Institute of Bone and Joint Research at the Royal North Shore Hospital.

  • Co-inventor of APC as a therapy in inflammation and skin disorders and publisher of over 90 papers on the subject.

Professor Silvio Danese
Program Lead - Inflammatory Bowel Disease
  • Professor of Gastroenterology IRCCS San Raffaele Hospital and of Gastroenterology at the Vita-Salute San Raffaele University.

  • Published more than 300 research articles in peer-reviewed journals. 

  • President of European Crohn’s and Colitis Organization (ECCO) and Secretary and Chair of the Clinical Trial task force of the International Organization of IBD (IOIBD).

Professor Laurent Mosnier
BSc, PhD
Program Lead - Cerebral Malaria
  • Professor, Department of Molecular Medicine, The Scripps Research Institute La Jolla

  • Inventor of P3R - the PAR3 agonist peptide.

  • Co-inventor of the G10 PAR1-PAR3 structure.

  • Published extensively in APC and cerebral malaria.

Management Team

Rob Antulov
BE (Hons), MBA
  • Experienced tech corporate adviser, with over 30 years' experience.

  • Advised on over 60 corporate transactions, in media, tech and biotech.

  • Current Chairman of Prokardia Therapeutics. 

  • Formerly Director of Strategy at Fairfax Media, senior marketing and strategy executive with Coca-Cola, and strategy consultant with Strategy& (Booz & Co).

Evan Siegel
BS, MS, M Phil, PhD
Strategy, Regs, Tox and CMC
  • CEO and President of Ground Zero Pharmaceuticals, Inc. -

  • Principal Regulatory Scientist & Director Regulatory Services, Quintiles Inc.

  • Director/Sr. Director, Regulatory Affairs and Corporate Compliance, Syntex, Inc. and Astra Inc.

  • Director of Pharmacology and Tox, Pharmaceutical Trade Association. 

  • Reviewing Toxicologist, US FDA.

Tom Gumley                 
BSc (Hons), PhD 
IP and Patenting Consultant 
  • Life sciences patent consultant with over 20+ years’ experience in biotech and pharma R&D. 

  • Formerly Principal, FPA Patent Attorneys and Partner at Freehills Patent Attorneys in Melbourne.

Jay Hennock
Chief Executive Officer
  • Over 30 years in corporate advisory services with Citibank, Bank of America.

  • Co-founded Access Systems and sold to International Gaming Technology Inc.

  • Co-founder & CFO of Nuon Therapeutics Inc. and founder and CEO of Bioatrix.

  • Sold Bioatrix to ZZ Biotech LLC - and is a Director and shareholder of ZZ Biotech.

Anchor 4
bottom of page